• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cyclacel Pharmaceuti (NQ: CYCC )

    1.670 -0.040 (-2.34%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 28,338
    Open 1.710
    Bid (Size) 1.550 (1)
    Ask (Size) 1.700 (4)
    Prev. Close 1.710
    Today's Range 1.610 - 1.750
    52wk Range 1.300 - 11.78
    Shares Outstanding 1,463,259
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions
    Lengthens Patent Exclusivity of Plogosertib until August 2040 
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -36.98%
    -36.98%
    1 Month
    +1.21%
    +1.21%
    3 Month
    -6.18%
    -6.18%
    6 Month
    -20.85%
    -20.85%
    1 Year
    -84.10%
    -84.10%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
    From Cyclacel
    Via GlobeNewswire
    Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
    From Cyclacel
    Via GlobeNewswire
    Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
    From Cyclacel
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Why Is Coursera (COUR) Stock Down 16% Today?
    Via InvestorPlace
    Why Is Medifast (MED) Stock Down 20% Today?
    Via InvestorPlace
    Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Is Greenwave Technology Solutions (GWAV) Stock Up 15% Today?
    Via InvestorPlace
    Why Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.